N-(3-溴苯基)-3-[(六氫-1H-氮雜卓-1-基)磺?；鵠-苯甲酰胺
| 中文名稱 | N-(3-溴苯基)-3-[(六氫-1H-氮雜卓-1-基)磺?；鵠-苯甲酰胺 |
|---|---|
| 中文同義詞 | N-(3-溴苯基)-3-[(六氫-1H-氮雜卓-1-基)磺?；鵠-苯甲酰胺;化合物AK-1;3-(氮雜環(huán)庚烷-1-基磺?；?-N-(3-溴苯基)苯甲酰胺;AK-7,中樞活性SIRT2抑制劑;化合物 AK-7;化合物AK-7,10 MM DMSO 溶液;AK-7?, ≥99% |
| 英文名稱 | 3-(azepan-1-ylsulfonyl)-N-(3-broMophenyl)benzaMide |
| 英文同義詞 | N-(3-Bromophenyl)-3-[(hexahydro-1H-azepin-1-yl)sulfonyl]-benzamide;SIRT2 Inhibitor,AK-7;N-(3-Bromophenyl)-3-[(hexahydro-1H-azepin-1-yl)sulfonyl]-benzamide SIRT2 Inhibitor,AK-7;AK 7, >=98%;3-(azepan-1-ylsulfonyl)-N-(3-broMophenyl)benzaMide;AK-7;Benzamide, N-(3-bromophenyl)-3-[(hexahydro-1H-azepin-1-yl)sulfonyl]-;AK-7;AK7;AK 7 |
| CAS號 | 420831-40-9 |
| 分子式 | C19H21BrN2O3S |
| 分子量 | 437.35 |
| EINECS號 | |
| 相關(guān)類別 | |
| Mol文件 | 420831-40-9.mol |
| 結(jié)構(gòu)式 |  |
N-(3-溴苯基)-3-[(六氫-1H-氮雜卓-1-基)磺酰基]-苯甲酰胺 性質(zhì)
| 密度 | 1.469±0.06 g/cm3(Predicted) |
|---|---|
| 儲存條件 | Sealed in dry,2-8°C |
| 溶解度 | 在DMSO中的溶解度≥15mg/mL |
| 形態(tài) | 粉末 |
| 酸度系數(shù)(pKa) | 12.28±0.70(Predicted) |
| 顏色 | 白色至棕褐色 |
| 穩(wěn)定性 | 從購買之日起 2 年內(nèi)保持穩(wěn)定。 DMSO 或乙醇溶液可在 -20℃ 下保存長達 3 個月。 |
| InChI | InChI=1S/C19H21BrN2O3S/c20-16-8-6-9-17(14-16)21-19(23)15-7-5-10-18(13-15)26(24,25)22-11-3-1-2-4-12-22/h5-10,13-14H,1-4,11-12H2,(H,21,23) |
| InChIKey | IYAYHZZWYNXHEQ-UHFFFAOYSA-N |
| SMILES | C(NC1=CC=CC(Br)=C1)(=O)C1=CC=CC(S(N2CCCCCC2)(=O)=O)=C1 |
|
SIRT2 15.5 μM (IC 50 ) |
AK-7 (10 μM) reduces cholesterol levels in naive N2a neuroblastoma cells and hippocampal slice cultures from wild-type mice. AK-7 (1 μM) shows neuroprotective effect of AK-7 in striatal Huntington’s disease (HD) neurons. AK-7 (12.5 μM) decreases ratio of DA neurons in primary midbrain cultures.
AK-7 (15 mg/kg/dose, i.p.) is brain-permeable in wild-type and HD mice. AK-7 (10, 20 mg/kg, i.p.) improves the behavior and neuropathological phenotype and extends survival of R6/2 HD mice. AK-7 (20 mg/kg) ameliorates HD neuropathology in R6/2 mice. AK-7 also reduces the polyglutamine aggregation in R6/2 brain. In addition, AK-7 treated 140CAG mice show motor performance changes that parallel untreated wild-type mice, with the 20 mg/kg dose being most effective and significantly different from untreated 140CAG mice.
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-16691 | N-(3-溴苯基)-3-[(六氫-1H-氮雜卓-1-基)磺酰基]-苯甲酰胺 AK-7 | 420831-40-9 | 1 mg | 306元 |
| 2026/06/05 | HY-16691 | N-(3-溴苯基)-3-[(六氫-1H-氮雜卓-1-基)磺?；鵠-苯甲酰胺 AK-7 | 420831-40-9 | 5 mg | 687元 |